Imaging of inflammation and calcification in aortic stenosis topical collection on cardiac PET, CT, and MRI

Current Cardiology Reports

Volumn 15, Issue 1, 2013, Pages

  Dweck, Marc R ^a,b   Joshi, Nikhil V ^a,b   Rudd, James H F ^c   Newby, David E ^a,b  

^a UNIVERSITY OF EDINBURGH   (United Kingdom)

^b UNIVERSITY OF EDINBURGH   (United Kingdom)

^c UNIVERSITY OF CAMBRIDGE   (United Kingdom)

Author keywords

Aortic stenosis; Calcification; Computed tomography; Inflammation; Positron emission tomography

Indexed keywords

BENZODIAZEPINE RECEPTOR; FLUCICLATIDE F 18; FLUORODEOXYGLUCOSE F 18; GLUCOSE; HYDROXYAPATITE; MATRIX METALLOPROTEINASE; SODIUM FLUORIDE F 18; SUPERPARAMAGNETIC IRON OXIDE NANOPARTICLE; TRACER;

ANGIOGENESIS; AORTA ATHEROSCLEROSIS; AORTA STENOSIS; AORTA VALVE; AORTA VALVE DISEASE; ARTIFACT REDUCTION; CALCIFICATION; CARDIAC IMAGING; CARDIOVASCULAR MAGNETIC RESONANCE; CLINICAL PRACTICE; CLINICAL RESEARCH; COMPUTER ASSISTED EMISSION TOMOGRAPHY; DISEASE ACTIVITY; DISEASE ASSOCIATION; DISEASE COURSE; DISEASE SEVERITY; DRUG ACTIVITY; DRUG TARGETING; DRUG UPTAKE; ENZYME ACTIVITY; FIBROSIS; GLUCOSE METABOLISM; HEART MUSCLE; HEART MUSCLE METABOLISM; HUMAN; HYPOXIA; IMAGING AND DISPLAY; INFLAMMATION; MACROPHAGE; METHODOLOGY; NEAR INFRARED SPECTROSCOPY; NON INVASIVE PROCEDURE; PATHOGENESIS; POSITRON EMISSION TOMOGRAPHY; REVIEW; THERMAL IMAGING; THREE DIMENSIONAL IMAGING; VALIDATION PROCESS; AORTA VALVE STENOSIS; CALCINOSIS; FEASIBILITY STUDY; SCINTISCANNING; VALVULAR HEART DISEASE;

AORTIC VALVE STENOSIS; CALCINOSIS; FEASIBILITY STUDIES; HEART VALVE DISEASES; HUMANS; INFLAMMATION; POSITRON-EMISSION TOMOGRAPHY AND COMPUTED TOMOGRAPHY;

EID: 84872771574     PISSN: 15233782     EISSN: 15343170     Source Type: Journal    
DOI: 10.1007/s11886-012-0320-8     Document Type: Review

References (45)

1. Cowell SJ, Newby DE, Prescott RJ, et al. A randomized trial of intensive lipid-lowering therapy in calcific aortic stenosis. N Engl J Med. 2005;352:2389-97. (Pubitemid 40958435)
2. Chan KL, Teo K, Dumesnil JG, Ni A, Tam J. Effect of Lipid lowering with rosuvastatin on progression of aortic stenosis: results of the aortic stenosis progression observation: measuring effects of rosuvastatin (ASTRONOMER) trial. Circulation. 2010;121:306-14.
3. Rossebo AB, Pedersen TR, Boman K, et al. Intensive lipid lowering with simvastatin and ezetimibe in aortic stenosis. N Engl J Med. 2008;359:1343-56.
4. Dweck MR, Boon NA, Newby DE. Calcific aortic stenosis: a disease of the valve and myocardium. J Am Coll Cardiol. 2012;60:1854-63.
5. O'Brien KD, Reichenbach DD, Marcovina SM, Kuusisto J, Alpers CE, Otto CM. Apolipoproteins B, (a), and E accumulate in the morphologically early lesion of 'degenerative' valvular aortic stenosis. Arterioscler Thromb Vasc Biol. 1996;16:523-32. (Pubitemid 26107723)
6. Olsson M, Thyberg J, Nilsson J. Presence of oxidized low density lipoprotein in nonrheumatic stenotic aortic valves. Arterioscler Thromb Vasc Biol. 1999;19:1218-22. (Pubitemid 29227640)
7. Ghaisas NK, Foley JB, O'Briain DS, Crean P, Kelleher D, Walsh M. Adhesion molecules in nonrheumatic aortic valve disease: endothelial expression, serum levels and effects of valve replacement. J Am Coll Cardiol. 2000;36:2257-62.
8. Jian B, Narula N, Li QY, Mohler III ER, Levy RJ. Progression of aortic valve stenosis: TGF-beta1 is present in calcified aortic valve cusps and promotes aortic valve interstitial cell calcification via apoptosis. Ann Thorac Surg. 2003;75:457-65. discussion 465-6. (Pubitemid 36184488)
9. Liu AC, Joag VR, Gotlieb AI. The emerging role of valve interstitial cell phenotypes in regulating heart valve pathobiology. Am J Pathol. 2007;171:1407-18. (Pubitemid 350158303)
10. Caira FC, Stock SR, Gleason TG, et al. Human degenerative valve disease is associated with up-regulation of low-density lipoprotein receptor-related protein 5 receptor-mediated bone formation. J Am Coll Cardiol. 2006;47:1707-12.
11. Mohler 3rd ER, Gannon F, Reynolds C, Zimmerman R, Keane MG, Kaplan FS. Bone formation and inflammation in cardiac valves. Circulation. 2001;103:1522-8. (Pubitemid 32226259)
12. Lin EC, Alavi A. PET and PET/CT. A clinical guide. New York; Stuttgart: Thieme; 2005.
13. • Rudd JH, Narula J, Strauss HW, et al. Imaging atherosclerotic plaque inflammation by fluorodeoxyglucose with positron emission tomography: ready for prime time? J Am Coll Cardiol. 2010;55:2527-35. Review article summarizing the literature investigating vascular 18F-FDG activity as a marker of plaque inflammation.
14. Rudd JH, Warburton EA, Fryer TD, et al. Imaging atherosclerotic plaque inflammation with [18F]-fluorodeoxyglucose positron emission tomography. Circulation. 2002;105:2708-11. (Pubitemid 34615139)
15. Tawakol A, Migrino RQ, Bashian GG, et al. In vivo 18F-fluorodeoxyglucose positron emission tomography imaging provides a noninvasive measure of carotid plaque inflammation in patients. J Am Coll Cardiol. 2006;48:1818-24. (Pubitemid 44648622)
16. Tahara N, Kai H, Ishibashi M, et al. Simvastatin attenuates plaque inflammation: evaluation by fluorodeoxyglucose positron emission tomography. J Am Coll Cardiol. 2006;48:1825-31. (Pubitemid 44648621)
17. Paulmier B, Duet M, Khayat R, et al. Arterial wall uptake of fluorodeoxyglucose on PET imaging in stable cancer disease patients indicates higher risk for cardiovascular events. J Nucl Cardiol. 2008;15:209-17. (Pubitemid 351396317)
18. Rominger A, Saam T, Wolpers S, et al. 18F-FDG PET/CT identifies patients at risk for future vascular events in an otherwise asymptomatic cohort with neoplastic disease. J Nucl Med. 2009;50:1611-20.
19. Muntendam P, McCall C, Sanz J, Falk E, Fuster V. The BioImage Study: novel approaches to risk assessment in the primary prevention of atherosclerotic cardiovascular disease - study design and objectives. Am Heart J. 2010;160:49-57 e1.
20. •• Dweck MR, Jones C, Joshi NV, et al. Assessment of valvular calcification and inflammation by positron emission tomography in patients with aortic stenosis. Circulation. 2012;125:76-86. This was the first prospective study to examine inflammation and calcification in aortic stenosis using PET/CT.
21. • Marincheva-Savcheva G, Subramanian S, Qadir S, et al. Imaging of the aortic valve using fluorodeoxyglucose positron emission tomography increased valvular fluorodeoxyglucose uptake in aortic stenosis. J Am Coll Cardiol. 2011;57:2507-15. A retrospective study of cancer patients demonstrating for the first time increased 18F-FDG activity in the valves of patients with aortic stenosis compared with those with normal valves.
22. Cheng VY, Slomka PJ, Ahlen M, Thomson LE, Waxman AD, Berman DS. Impact of carbohydrate restriction with and without fatty acid loading on myocardial (18)F-FDG uptake during PET: a randomized controlled trial. J Nucl Cardiol. 2010;17:286-91.
23. Wykrzykowska J, Lehman S, Williams G, et al. Imaging of inflamed and vulnerable plaque in coronary arteries with 18F-FDG PET/CT in patients with suppression of myocardial uptake using a low-carbohydrate, high-fat preparation. J Nucl Med. 2009;50:563-8.
24. Blau M, Ganatra R, Bender MA. 18F-fluoride for bone imaging. Semin Nucl Med. 1972;2:31-7.
25. Foldager CB, Bendtsen M, Bunger C. PET scanning for evaluation of bone metabolism. Acta Orthop. 2009;80:737-8. author reply 738-9.
26. Hawkins RA, Choi Y, Huang SC, et al. Evaluation of the skeletal kinetics of fluorine-18-fluoride ion with PET. J Nucl Med. 1992;33:633-42.
27. Messa C, Goodman WG, Hoh CK, et al. Bone metabolic activity measured with positron emission tomography and [18F]fluoride ion in renal osteodystrophy: correlation with bone histomorphometry. J Clin Endocrinol Metab. 1993;77:949-55. (Pubitemid 23301469)
28. Piert M, Zittel TT, Becker GA, et al. Assessment of porcine bone metabolism by dynamic. J Nucl Med. 2001;42:1091-100.
29. Cook GJ, Blake GM, Marsden PK, Cronin B, Fogelman I. Quantification of skeletal kinetic indices in Paget's disease using dynamic 18F-fluoride positron emission tomography. J Bone Miner Res. 2002;17:854-9. (Pubitemid 34441902)
30. Frost ML, Fogelman I, Blake GM, Marsden PK, Cook Jr G. Dissociation between global markers of bone formation and direct measurement of spinal bone formation in osteoporosis. J Bone Miner Res. 2004;19:1797-804. (Pubitemid 41103430)
31. Derlin T, Richter U, Bannas P, et al. Feasibility of 18F-sodium fluoride PET/CT for imaging of atherosclerotic plaque. J Nucl Med. 2010;51:862-5.
32. Derlin T, Wisotzki C, Richter U, et al. In vivo imaging of mineral deposition in carotid plaque using 18F-sodium fluoride PET/CT: correlation with atherogenic risk factors. J Nucl Med. 2011;52:362-8.
33. Dweck MR, Chow MW, Joshi NV, et al. Coronary arterial 18F-sodium fluoride uptake: a novel marker of plaque biology. J Am Coll Cardiol. 2012;59:1539-48.
34. Houslay ES, Cowell SJ, Prescott RJ, et al. Progressive coronary calcification despite intensive lipid-lowering treatment: a randomised controlled trial. Heart. 2006;92:1207-12. (Pubitemid 44298857)
35. Arad Y, Spadaro LA, Roth M, Newstein D, Guerci AD. Treatment of asymptomatic adults with elevated coronary calcium scores with atorvastatin, vitamin C, and vitamin E: the St. Francis Heart Study randomized clinical trial. J Am Coll Cardiol. 2005;46:166-72. (Pubitemid 40905146)
36. Raggi P, Davidson M, Callister TQ, et al. Aggressive vs moderate lipid-lowering therapy in hypercholesterolemic postmenopausal women: beyond endorsed lipid lowering with EBT scanning (BELLES). Circulation. 2005;112:563-71. (Pubitemid 41060797)
37. • Folco EJ SY, Rocha VZ, Christen T, Shvartz E, Sukhova GK, Di Carli MF, et al. Hypoxia but not inflammation augments glucose uptake in human macrophages. J Am Coll Cardiol. 2011;58:603-14. In vitro study examining the mechanisms underlying 18-FDG activity in the vasculature, which suggested that hypoxia increases macrophage uptake.
38. Bird JL, Izquierdo-Garcia D, Davies JR, et al. Evaluation of translocator protein quantification as a tool for characterising macrophage burden in human carotid atherosclerosis. Atherosclerosis. 2010;210:388-91.
39. Kenny LM, Coombes RC, Oulie I, et al. Phase I trial of the positron-emitting Arg-Gly-Asp (RGD) peptide radioligand 18F-AH111585 in breast cancer patients. J Nucl Med. 2008;49:879-86. (Pubitemid 351793427)
40. Verjans J, Wolters S, Laufer W, et al. Early molecular imaging of interstitial changes in patients after myocardial infarction: comparison with delayed contrast-enhanced magnetic resonance imaging. J Nucl Cardiol. 2010;17:1065-72.
41. Furumoto S, Takashima K, Kubota K, Ido T, Iwata R, Fukuda H. Tumor detection using 18F-labeled matrix metalloproteinase-2 inhibitor. Nucl Med Biol. 2003;30:119-25. (Pubitemid 36293712)
42. Toutouzas K, Drakopoulou M, Synetos A, et al. In vivo aortic valve thermal heterogeneity in patients with nonrheumatic aortic valve stenosis the: first in vivo experience in humans. J Am Coll Cardiol. 2008;52:758-63.
43. Richards JM, Semple SI, MacGillivray TJ, et al. Abdominal aortic aneurysm growth predicted by uptake of ultrasmall superparamagnetic particles of iron oxide: a pilot study. Circ Cardiovasc Imaging. 2011;4:274-81.
44. New SE, Aikawa E. Molecular imaging insights into early inflammatory stages of arterial and aortic valve calcification. Circ Res. 2011;108:1381-91.
45. Yoo H, Kim JW, Shishkov M, et al. Intra-arterial catheter for simultaneous microstructural and molecular imaging in vivo. Nat Med. 2011;17:1680-4.